Faeth Therapeutics Q2 EPS $(2.84) Beats $(3.29) Estimate
Faeth Therapeutics (NASDAQ:FTH) reported quarterly losses of $(2.84) per share which beat the analyst consensus estimate of $(3.29) by 13.68 percent. This is a 27.37 percent increase over losses of $(3.91) per share
Faeth Therapeutics lost less money than experts thought it would, which is good news when a company is still spending a lot. Watch whether the company keeps getting better at controlling its costs, because that shows progress even before it makes a profit.
Last session drawn · prints held ~15 minutes · licensed exchange data
Source: Benzinga · Read the original report at the publisher. Headline and figures shown for context; data may be delayed.
Disclosure: Educational and informational purposes only — not financial advice. We educate, not advise. Market data may be delayed up to 15 minutes unless marked real-time. Past performance is not indicative of future results.